(NewsDirect)
Valeo Pharma CEO Steve Saviuk joined SteveDarling from Proactive to share guidance for the company’ssecond-quarter that reveal it is heading for the sixth straightquarter of record revenue.
Thecompany said it expects 2Q revenue to exceed $13.5 million while itsadjusted underlying (EBITDA) loss will decrease to below $2 million asthe company heads to profitability.
Saviuk told Proactive thenumber continues to be driven by Asthma medications ENERZAIR andATECTURA which saw quarterly revenues grow 270% over this time lastyear. In fact, the total number of prescribing physicians also grewand is now expected to exceeds 2,000.
ContactDetails
Proactive Investors
+1 347-449-0879
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.